352 related articles for article (PubMed ID: 31515132)
1. Immunogenicity of RNA Replicons Encoding HIV Env Immunogens Designed for Self-Assembly into Nanoparticles.
Melo M; Porter E; Zhang Y; Silva M; Li N; Dobosh B; Liguori A; Skog P; Landais E; Menis S; Sok D; Nemazee D; Schief WR; Weiss R; Irvine DJ
Mol Ther; 2019 Dec; 27(12):2080-2090. PubMed ID: 31515132
[TBL] [Abstract][Full Text] [Related]
2. Glycan Masking Focuses Immune Responses to the HIV-1 CD4-Binding Site and Enhances Elicitation of VRC01-Class Precursor Antibodies.
Duan H; Chen X; Boyington JC; Cheng C; Zhang Y; Jafari AJ; Stephens T; Tsybovsky Y; Kalyuzhniy O; Zhao P; Menis S; Nason MC; Normandin E; Mukhamedova M; DeKosky BJ; Wells L; Schief WR; Tian M; Alt FW; Kwong PD; Mascola JR
Immunity; 2018 Aug; 49(2):301-311.e5. PubMed ID: 30076101
[TBL] [Abstract][Full Text] [Related]
3. Elicitation of Neutralizing Antibody Responses to HIV-1 Immunization with Nanoparticle Vaccine Platforms.
Murji AA; Qin JS; Hermanus T; Morris L; Georgiev IS
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372503
[TBL] [Abstract][Full Text] [Related]
4. Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice.
McGuire AT; Gray MD; Dosenovic P; Gitlin AD; Freund NT; Petersen J; Correnti C; Johnsen W; Kegel R; Stuart AB; Glenn J; Seaman MS; Schief WR; Strong RK; Nussenzweig MC; Stamatatos L
Nat Commun; 2016 Feb; 7():10618. PubMed ID: 26907590
[TBL] [Abstract][Full Text] [Related]
5. B cells expressing authentic naive human VRC01-class BCRs can be recruited to germinal centers and affinity mature in multiple independent mouse models.
Huang D; Abbott RK; Havenar-Daughton C; Skog PD; Al-Kolla R; Groschel B; Blane TR; Menis S; Tran JT; Thinnes TC; Volpi SA; Liguori A; Schiffner T; Villegas SM; Kalyuzhniy O; Pintea M; Voss JE; Phelps N; Tingle R; Rodriguez AR; Martin G; Kupryianov S; deCamp A; Schief WR; Nemazee D; Crotty S
Proc Natl Acad Sci U S A; 2020 Sep; 117(37):22920-22931. PubMed ID: 32873644
[TBL] [Abstract][Full Text] [Related]
6. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
[TBL] [Abstract][Full Text] [Related]
7. Structural and functional evaluation of de novo-designed, two-component nanoparticle carriers for HIV Env trimer immunogens.
Antanasijevic A; Ueda G; Brouwer PJM; Copps J; Huang D; Allen JD; Cottrell CA; Yasmeen A; Sewall LM; Bontjer I; Ketas TJ; Turner HL; Berndsen ZT; Montefiori DC; Klasse PJ; Crispin M; Nemazee D; Moore JP; Sanders RW; King NP; Baker D; Ward AB
PLoS Pathog; 2020 Aug; 16(8):e1008665. PubMed ID: 32780770
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen.
Jardine JG; Ota T; Sok D; Pauthner M; Kulp DW; Kalyuzhniy O; Skog PD; Thinnes TC; Bhullar D; Briney B; Menis S; Jones M; Kubitz M; Spencer S; Adachi Y; Burton DR; Schief WR; Nemazee D
Science; 2015 Jul; 349(6244):156-61. PubMed ID: 26089355
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 VRC01 Germline-Targeting Immunogens Select Distinct Epitope-Specific B Cell Receptors.
Lin YR; Parks KR; Weidle C; Naidu AS; Khechaduri A; Riker AO; Takushi B; Chun JH; Borst AJ; Veesler D; Stuart A; Agrawal P; Gray M; Pancera M; Huang PS; Stamatatos L
Immunity; 2020 Oct; 53(4):840-851.e6. PubMed ID: 33053332
[TBL] [Abstract][Full Text] [Related]
10. Effect of HIV-1 envelope cytoplasmic tail on adenovirus primed virus encoded virus-like particle immunizations.
Andersson AC; Ragonnaud E; Seaton KE; Sawant S; Folgori A; Colloca S; Labranche C; Montefiori DC; Tomaras GD; Holst PJ
Vaccine; 2016 Oct; 34(44):5344-5351. PubMed ID: 27633665
[TBL] [Abstract][Full Text] [Related]
11. Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice.
Sok D; Briney B; Jardine JG; Kulp DW; Menis S; Pauthner M; Wood A; Lee EC; Le KM; Jones M; Ramos A; Kalyuzhniy O; Adachi Y; Kubitz M; MacPherson S; Bradley A; Friedrich GA; Schief WR; Burton DR
Science; 2016 Sep; 353(6307):1557-1560. PubMed ID: 27608668
[TBL] [Abstract][Full Text] [Related]
12. mRNA-LNP prime boost evolves precursors toward VRC01-like broadly neutralizing antibodies in preclinical humanized mouse models.
Wang X; Cottrell CA; Hu X; Ray R; Bottermann M; Villavicencio PM; Yan Y; Xie Z; Warner JE; Ellis-Pugh JR; Kalyuzhniy O; Liguori A; Willis JR; Menis S; Rämisch S; Eskandarzadeh S; Kubitz M; Tingle R; Phelps N; Groschel B; Himansu S; Carfi A; Kirsch KH; Weldon SR; Nair U; Schief WR; Batista FD
Sci Immunol; 2024 May; 9(95):eadn0622. PubMed ID: 38753808
[TBL] [Abstract][Full Text] [Related]
13. Overcoming Steric Restrictions of VRC01 HIV-1 Neutralizing Antibodies through Immunization.
Parks KR; MacCamy AJ; Trichka J; Gray M; Weidle C; Borst AJ; Khechaduri A; Takushi B; Agrawal P; Guenaga J; Wyatt RT; Coler R; Seaman M; LaBranche C; Montefiori DC; Veesler D; Pancera M; McGuire A; Stamatatos L
Cell Rep; 2019 Dec; 29(10):3060-3072.e7. PubMed ID: 31801073
[TBL] [Abstract][Full Text] [Related]
14. mRNA-LNP HIV-1 trimer boosters elicit precursors to broad neutralizing antibodies.
Xie Z; Lin YC; Steichen JM; Ozorowski G; Kratochvil S; Ray R; Torres JL; Liguori A; Kalyuzhniy O; Wang X; Warner JE; Weldon SR; Dale GA; Kirsch KH; Nair U; Baboo S; Georgeson E; Adachi Y; Kubitz M; Jackson AM; Richey ST; Volk RM; Lee JH; Diedrich JK; Prum T; Falcone S; Himansu S; Carfi A; Yates JR; Paulson JC; Sok D; Ward AB; Schief WR; Batista FD
Science; 2024 May; 384(6697):eadk0582. PubMed ID: 38753770
[TBL] [Abstract][Full Text] [Related]
15. Presentation of HIV-1 envelope glycoprotein trimers on diverse nanoparticle platforms.
Brouwer PJM; Sanders RW
Curr Opin HIV AIDS; 2019 Jul; 14(4):302-308. PubMed ID: 30994503
[TBL] [Abstract][Full Text] [Related]
16. Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies.
McGuire AT; Hoot S; Dreyer AM; Lippy A; Stuart A; Cohen KW; Jardine J; Menis S; Scheid JF; West AP; Schief WR; Stamatatos L
J Exp Med; 2013 Apr; 210(4):655-63. PubMed ID: 23530120
[TBL] [Abstract][Full Text] [Related]
17. Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses.
Perdiguero B; Gómez CE; García-Arriaza J; Sánchez-Corzo C; Sorzano CÓS; Wilmschen S; von Laer D; Asbach B; Schmalzl C; Peterhoff D; Ding S; Wagner R; Kimpel J; Levy Y; Pantaleo G; Esteban M
Front Immunol; 2019; 10():2941. PubMed ID: 31921191
[TBL] [Abstract][Full Text] [Related]
18. Induction of Tier 1 HIV Neutralizing Antibodies by Envelope Trimers Incorporated into a Replication Competent Vesicular Stomatitis Virus Vector.
Bresk CA; Hofer T; Wilmschen S; Krismer M; Beierfuß A; Effantin G; Weissenhorn W; Hogan MJ; Jordan APO; Gelman RS; Montefiori DC; Liao HX; Schmitz JE; Haynes BF; von Laer D; Kimpel J
Viruses; 2019 Feb; 11(2):. PubMed ID: 30769947
[TBL] [Abstract][Full Text] [Related]
19. Modulating the quantity of HIV Env-specific CD4 T cell help promotes rare B cell responses in germinal centers.
Lee JH; Hu JK; Georgeson E; Nakao C; Groschel B; Dileepan T; Jenkins MK; Seumois G; Vijayanand P; Schief WR; Crotty S
J Exp Med; 2021 Feb; 218(2):. PubMed ID: 33355623
[TBL] [Abstract][Full Text] [Related]
20. Rational HIV immunogen design to target specific germline B cell receptors.
Jardine J; Julien JP; Menis S; Ota T; Kalyuzhniy O; McGuire A; Sok D; Huang PS; MacPherson S; Jones M; Nieusma T; Mathison J; Baker D; Ward AB; Burton DR; Stamatatos L; Nemazee D; Wilson IA; Schief WR
Science; 2013 May; 340(6133):711-6. PubMed ID: 23539181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
